title: Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.
authors.forename: Ken
authors.initials: K
authors.lastname: Garber
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016527:Drug Costs; D004345:Drug Industry; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D009316:National Institutes of Health (U.S.); D010880:Piperidines / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D011758:Pyrroles / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; D053612:Janus Kinases